Status:
RECRUITING
Clinical Study of Stellate Ganglion Block in Treatment of Patients With Advanced Primary Parkinson's Disease
Lead Sponsor:
Zhujiang Hospital
Conditions:
Stellate Ganglion
Parkinson Disease
Eligibility:
All Genders
40-85 years
Phase:
NA
Brief Summary
At present, there are no reports on the application of stellate ganglion block in the treatment of Parkinson's disease patients at home and abroad. Based on the preliminary clinical observation, this ...
Detailed Description
Parkinson's disease (PD) is a relatively common degenerative disease of the central nervous system. In the past few decades, China's population has increased significantly, resulting in a rapid increa...
Eligibility Criteria
Inclusion
- Patients with Parkinson's disease who met the diagnostic criteria for MDS as "probable PD" or" confirmed PD" in 2016
- Inclusion criteria:
- Age 40-85;
- Patients with Parkinson's disease who met the diagnostic criteria of MDS as "probable PD" or" confirmed PD" in 2016;
- The patient or his/her legal guardian agrees to participate in the study and signs the informed consent;
- Hoehn-yahr (H\&Y) 2.5 \~ 5;
Exclusion
- 1\. Allergic to local anesthetic drugs;
- 2\. Unable to cooperate with motor or non-motor function monitoring;
- 3\. Patients with Parkinson's superposition syndrome, such as cortical basal ganglia degeneration, lewy body dementia, multisystem atrophy and progressive supranuclear palsy, were excluded; Patients with secondary Parkinson's disease, such as vascular Parkinson's disease, drug toxicity or traumatic Parkinson's disease;
- 4\. Refuse to sign the consent form.
Key Trial Info
Start Date :
July 28 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2024
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT06112392
Start Date
July 28 2023
End Date
June 30 2024
Last Update
January 31 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhujiang Hospiatal
Guangzhou, Guangdong, China, 510000